Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Trump Effect On Drug Pricing: Uncertainty Is The Only Constant

Executive Summary

Those “massive” price cuts US President Trump said would be announced this week? Never mind.

You may also be interested in...

Gilead’s Price Reduction Strategy: A Serious Move, But Not A Long-Term Model For US

“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.

Drug Pricing Response: The 1,000-Day Report

HHS’ “First 100 Days” take on the drug pricing “Blueprint” is a novel use of a tried-and-true milestone for presidential action. But it is probably more enlightening to look at what has happened in the 1,000 days since drug pricing became the overwhelming focus of political attention.

US Senators Seek 'Clarity’ On Middlemen Obstructing List Price Reductions

Letters to several pharmacy benefit managers and wholesalers request information on whether middlemen have discouraged decrease in list prices.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts